ArticlePharmaceutical research2015
RGD Peptide-Pegylated PLLA Nanoparticles Containing Epirubicin Hydrochloride Exhibit Receptor-Dependent Tumor Trafficking In Vitro and In Vivo.
Article in Pharmaceutical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Therapy of cervical cancer usingThe Journal of international medical research · 2018Article
- Targeting assay of a fusion protein applied in enzyme prodrug therapy.Oncology letters · 2017Article
Corrections and comments
- Retraction · 2016-02-02Concerns/Issues about Data · Notice - Limited or No Information ·
- Retracted
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA novel hydrophilic conjugate of arginine-glycine-aspartic acid (RGD) and polyethylene glycol (PEG), i.e., RGD-PEG Mw (M W = 300, 600, 1000 or 4000), was synthesized and employed in epirubicin (EPI) loaded poly L-lactic acid (PLLA) nanoparticles (NPs) to improve its tumor targeting effect.
methodsIn vitro studies were performed to assess EPI release from NPs in tumor-mimic acidic medium, cytotoxicity and cell cycle assay in HepG2 cells, and cellular uptake kinetics in four types of tumor cells including A375 cells (high integrin receptor expression), HeLa cells (low integrin receptor expression), and metabolic HepG2/SMMC7721 cells. In vivo pharmacodynamics (PD) and pharmacokinetic (PK) studies were determined in a murine ascites tumor model.
resultsCellular uptake kinetics showed integrin receptor-dependent binding and internalization. In vitro release results showed that PLLA and PEG groups retarded EPI release from NPs and promoted drug release amount in acidic medium, which benefited in vivo trafficking to the acidic tumors. In vivo PD and PK studies revealed that RGD-PEG Mw (M W = 600 ~ 1000) improved tumor targeting capacity of NPs by ~2.4-fold, compared to conventional EPI NPs.
conclusionsRGD-PEG Mw (M W = 600 ~ 1000) modified PLLA NPs provide a promising strategy to improve tumor selectivity in cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.